Skip to main content
. 2019 Jul 30;6(3):82. doi: 10.3390/medicines6030082

Figure 1.

Figure 1

(A) Comparison of the main genetic alterations (copy number alterations and mutations) observed in primary and metastatic prostate cancer. The data are reported in the study of the Cancer Genome Atlas Project (TCGA) [38]. (B) Comparison of the alterations in signaling and biochemical pathways observed in primary and metastatic prostate cancer. The data are reported in Armenia et al. [61]. (C) Common genomic alterations observed in prostate cancer (mostly primary cancers) patients subdivided according to the presence of ERG gene fusions into ETS+ and ETS-. The data are reported in Wedge et al. 2018 [65]. (D) Common genomic alterations observed in primary prostate cancer patients subdivided into ETS+ and ETS- groups according to the presence of ETS gene fusions. Data are reported in Xiao et al., 2018 [66].